Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Keratosis, Actinic 2Breast Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Pain 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Hodgkin Disease 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal, Breast 1Bone Neoplasms 1

Interventions

Sorafenib 3atezolizumab 2Radiotherapy 2Bevacizumab 2tremelimumab 1temsirolimus 1lonafarnib 1liposomal doxorubicin 1infigratinib 1gadolinium ethoxybenzyl DTPA 1fludarabine 1durvalumab 1cabozantinib 1bavituximab 1aldesleukin 1Thoracoscopy 1Thoracic Surgery, Video-Assisted 1Resveratrol 1Radiosurgery 1Radionuclide Generators 1Radiofrequency Ablation 1Polymerase Chain Reaction 1Oxaliplatin 1Nivolumab 1NSC 366140 1Mass Spectrometry 1Immunotherapy 1Immunohistochemistry 1Genetic Testing 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liver Neoplasms × Cryotherapy × Clear all
NCT03484962 2020-10-19

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer

Fuda Cancer Hospital, Guangzhou

Phase 2 Withdrawn
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡